NCT01333293View on ClinicalTrials.gov

The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

October 31, 2015

Study Completion Date

January 31, 2016

Conditions
Mastocytosis
Interventions
DRUG

injections

subcutaneous injections

Trial Locations (3)

Unknown

University Hospital Berne (Insel) and Zieglerspital Berne, Bern

Geneva University Hospitals and Medical Faculty of the University of Geneva, Geneva

Allergy Unit, Department of Dermatology, University Hospital Zurich, Zurich

All Listed Sponsors
lead

University of Zurich

OTHER

NCT01333293 - The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients | Biotech Hunter | Biotech Hunter